Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Cytokinetics, Inc.    CYTK

Delayed Quote. Delayed  - 08/22 09:59:59 pm
12.55 USD   --.--%
08/11 INSIDER TRADING : CYTK) – Insider Sold 11,348 shares of Stock
08/03 INSIDER TRADING : CYTK) – CEO Sold 5,000 shares of Stock
08/02 CYTOKINETICS : reports 2Q loss
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Cytokinetics, Incorporated (NASDAQ:CYTK) Files An 8-K Submission of Matters to a Vote of Security Holders

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/19/2017 | 10:58pm CEST

Cytokinetics, Incorporated (NASDAQ:CYTK) Files An 8-K Submission of Matters to a Vote of Security Holders

Item5.07.

Submission of Matters to a Vote of Security
Holders.

The following is a brief description of each matter voted upon at
the Annual Meeting, as well as the number of votes cast for or
against each matter and the number of abstentions and broker
non-votes with respect to each matter. Of the 43,241,281 shares
of the Companys common stock entitled to vote at the Annual
Meeting, 38,927,533 shares of common stock, or 90.02%, of the
total eligible votes to be cast, were represented at the Annual
Meeting in person or by proxy, constituting a quorum. A more
complete description of each matter is set forth in the Companys
definitive proxy statement for the Annual Meeting, which was
filed with the Securities and Exchange Commission on March31,
2017.

Proposal 1: Election of Directors

The stockholders elected L. Patrick Gage, Edward M. Kaye and
Wendell Wierenga as ClassI Directors, each to serve for a
three-year term and until their successors are duly elected and
qualified. The voting for each director was as follows:

Name

For

Withheld

BrokerNon-Vote

L. Patrick Gage

31,235,018 143,950 7,548,565

Edward M. Kaye

30,838,654 540,314 7,548,565

Wendell Wierenga

31,162,950 216,018 7,548,565

Proposal 2: Ratification of Independent Registered
Public Accounting Firm

The stockholders ratified the selection by the Audit Committee of
the Board of Directors of PricewaterhouseCoopers LLP as the
Companys independent registered public accounting firm for the
fiscal year ending December31, 2017. The votes were as follows:

For

Against

Abstain

38,714,180

172,993 40,360

Proposal 3: Approval of an amendment to the Amended
and Restated 2004 Equity Incentive Plan to increase the number of
authorized shares reserved for issuance under the Amended and
Restated 2004 Equity Incentive Plan.

The stockholders approved the Amended and Restated 2004 Equity
Incentive Plan to increase the number of authorized shares
reserved for issuance under the Amended and Restated 2004 Equity
Incentive Plan by 3,900,000 shares. The votes were as follows:

For

Against

Abstain

Broker Non-Vote

19,689,832

7,562,216 4,126,920 7,548,565

Proposal 4: Advisory Vote on Executive
Compensation

The stockholders approved, on an advisory basis, the compensation
of the named executive officers, as disclosed in the Companys
Proxy Statement for the 2017 Annual Meeting of Shareholders. The
votes were as follows:

For

Against

Abstain

Broker Non-Vote

31,058,363

282,247 38,358 7,548,565

Proposal 5: Advisory Vote on Frequency of Say On
Pay

The stockholders voted, on an advisory basis, that future
advisory votes on executive compensation should be submitted to
the stockholders every year. The votes were as follows:

Every three years

Every two years

Every year

Abstain from voting

Broker Non-Vote

7,547,820

78,240 23,732,163 20,745 7,548,565

About Cytokinetics, Incorporated (NASDAQ:CYTK)
Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. Its drug candidates, which are in clinical development include tirasemtiv, CK-2127107 and omecamtiv mecarbil. Its tirasemtiv and CK-2127107 are skeletal muscle troponin activators. It is developing tirasemtiv drug candidate for the treatment of Amyotrophic lateral sclerosis (ALS). The Company is developing CK-2127107 for the potential treatment of spinal muscular atrophy, chronic obstructive pulmonary disease and ALS. The Omecamtiv mecarbil is a cardiac muscle myosin activator, which is being evaluated for the treatment of heart failure. Cytokinetics, Incorporated (NASDAQ:CYTK) Recent Trading Information
Cytokinetics, Incorporated (NASDAQ:CYTK) closed its last trading session down -0.05 at 14.20 with 533,867 shares trading hands.

The post Cytokinetics, Incorporated (NASDAQ:CYTK) Files An 8-K Submission of Matters to a Vote of Security Holders appeared first on Market Exclusive.

© Market Exclusive 2017, source Market Exclusive

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CYTOKINETICS, INC.
08/17 CYTOKINETICS : CK-107 Muscles In at Phase 2
08/11 INSIDER TRADING ACTIVITY CYTOKINETIC : CYTK) – Insider Sold 11,348 shares ..
08/04 CYTOKINETICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND R..
08/04 CYTOKINETICS, INC. : Featured Company News - Cytokinetics Announces Positive Res..
08/03 CYTOKINETICS : Announces Positive Results From Phase 2 Clinical Trial of Omecamt..
08/03 INSIDER TRADING ACTIVITY CYTOKINETIC : CYTK) – CEO Sold 5,000 shares of St..
08/02 CYTOKINETICS : reports 2Q loss
08/02 CYTOKINETICS, INCORPORATED (NASDAQ : CYTK) Files An 8-K Results of Operations an..
08/02 CYTOKINETICS INC : Results of Operations and Financial Condition, Financial Stat..
08/02 Cytokinetics, Inc. Reports Second Quarter 2017 Financial Results
More news
News from SeekingAlpha
08/05 Stocks to watch next week
08/02 Cytokinetics' (CYTK) CEO Robert Blum on Q2 2017 Results - Earnings Call Trans..
08/02 Cytokinetics misses by $0.03, misses on revenue
08/02 Cytokinetics' omecamtiv mecarbil shows positive effect in mid-stage heart fai..
07/27 Cytokinetics launches mid-stage study of CK-2127107 in ALS
Financials ($)
Sales 2017 20,7 M
EBIT 2017 -106 M
Net income 2017 -102 M
Finance 2017 191 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 23,3x
EV / Sales 2018 12,2x
Capitalization 674 M
Chart CYTOKINETICS, INC.
Duration : Period :
Cytokinetics, Inc. Technical Analysis Chart | CYTK | US23282W6057 | 4-Traders
Technical analysis trends CYTOKINETICS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 21,9 $
Spread / Average Target 74%
EPS Revisions
Managers
NameTitle
Robert I. Blum President, Chief Executive Officer & Director
L. Patrick Gage Chairman
Ching Jaw Chief Financial Officer & Senior Vice President
Andrew A. Wolff Chief Medical Officer & Senior Vice President
Fady Ibraham Malik Executive Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
CYTOKINETICS, INC.3.29%674
AMGEN16.32%124 096
CELGENE CORPORATION10.09%101 932
GILEAD SCIENCES0.70%95 777
REGENERON PHARMACEUTICALS27.48%51 288
VERTEX PHARMACEUTICALS111.05%39 199